| A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis A Vecchione, B Belletti, F Lovat, S Volinia, G Chiappetta, S Giglio, ... Proceedings of the National Academy of Sciences 110 (24), 9845-9850, 2013 | 183 | 2013 |
| The use of bevacizumab in non-small cell lung cancer: an update S Lauro, CE Onesti, R Righini, P Marchetti Anticancer research 34 (4), 1537-1545, 2014 | 84 | 2014 |
| The sexist behaviour of immune checkpoint inhibitors in cancer therapy? A Botticelli, CE Onesti, I Zizzari, B Cerbelli, P Sciattella, M Occhipinti, ... Oncotarget 8 (59), 99336, 2017 | 40 | 2017 |
| High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art R Falcone, M Roberto, C D’Antonio, A Romiti, A Milano, CE Onesti, ... Digestive and Liver Disease 48 (12), 1503-1505, 2016 | 27 | 2016 |
| Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines F Mazzuca, CE Onesti, M Roberto, M Di Girolamo, A Botticelli, P Begini, ... Oncotarget 9 (39), 25714, 2018 | 25 | 2018 |
| Continuous, low-dose capecitabine for patients with recurrent colorectal cancer A Romiti, CE Onesti, M Roberto, V Barucca, S Tomao, C D’Antonio, ... Medical Oncology 32 (3), 54, 2015 | 25 | 2015 |
| Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know C D'ANTONIO, A Milano, R Righini, CE Onesti, M Bassanelli, R Falcone, ... Anticancer research 34 (10), 5241-5250, 2014 | 22 | 2014 |
| Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival M Roberto, A Botticelli, L Strigari, M Ghidini, CE Onesti, M Ratti, I Benzoni, ... Medical oncology 35 (7), 1-9, 2018 | 17 | 2018 |
| Precision medicine for metastatic breast cancer. AF Deluche E, Onesti E Am Soc Clin Oncol Educ Book 35, e2-e7, 2015 | 17 | 2015 |
| Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients: potential role in clinical practice A Milano, F Mazzetta, S Valente, D Ranieri, L Leone, A Botticelli, ... Analytical Cellular Pathology 2018, 2018 | 16 | 2018 |
| Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure CE Onesti, A Romiti, M Roberto, R Falcone, P Marchetti Expert review of anticancer therapy 15 (10), 1183-1198, 2015 | 14 | 2015 |
| Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment CE Onesti, P Frères, G Jerusalem Journal of thoracic disease 11 (1), 35, 2019 | 13 | 2019 |
| A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer M Roberto, A Romiti, CE Onesti, C D’Antonio, A Milano, R Falcone, ... Anti-cancer drugs 27 (2), 106-111, 2016 | 13 | 2016 |
| Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment: a case report M Occhipinti, R Falcone, CE Onesti, P Marchetti Drug safety-case reports 5 (1), 1-4, 2018 | 10 | 2018 |
| Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine M Roberto, A Romiti, A Botticelli, F Mazzuca, L Lionetto, G Gentile, I Paris, ... European journal of clinical pharmacology 73 (2), 157-164, 2017 | 10 | 2017 |
| Oncological care organisation during COVID-19 outbreak CE Onesti, HS Rugo, D Generali, M Peeters, K Zaman, H Wildiers, ... ESMO open 5 (4), e000853, 2020 | 9 | 2020 |
| Changes of microbiome profile during nivolumab treatment in NSCLC patients. A Botticelli, L Putignani, I Zizzari, F Del Chierico, S Reddel, F Di Pietro, ... Journal of Clinical Oncology 36 (15_suppl), e15020-e15020, 2018 | 9 | 2018 |
| 5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX CE Onesti, A Botticelli, M La Torre, M Borro, G Gentile, A Romiti, ... Anti-cancer drugs 28 (3), 322-326, 2017 | 9 | 2017 |
| Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer M Borro, A Botticelli, F Mazzuca, EC Onesti, G Gentile, A Romiti, ... Oncotarget 8 (8), 14050, 2017 | 9 | 2017 |
| The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer A Romiti, M Roberto, C D’Antonio, CE Onesti, V Barucca, A Milano, ... Anti-cancer drugs 27 (10), 1044-1049, 2016 | 9 | 2016 |
Maurizio SimmacoUniversità La Sapienza - Azienda Ospedaliera Sant'Andrea - RomaVerified email at uniroma1.it
